25698-18-4

Basic information

• Product Name: (R)-2-amino-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid
• Synonyms: (R)-2-amino-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid
• CAS NO: 25698-18-4
• Molecular Weight: 236.054
• Mol File: 25698-18-4.mol

Chemical Properties

• CAS DataBase Reference: (R)-2-amino-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-amino-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid(25698-18-4)
• EPA Substance Registry System: (R)-2-amino-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid(25698-18-4)

Safety Data

• Hazardous Substances Data: 25698-18-4(Hazardous Substances Data)

Upstream product

• 69598-75-0 complestatin 
• 22818-40-2 D-4-hydroxyphenylglycine 

Downstream Products

• 1027761-55-2 (R)-2-(((9H-fluoren-9-yl)-methoxy)carbonylamino)-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid 
• 872877-33-3 2-benzyloxycarbonylamino-3-[6-(5-{[2-tert-butoxycarbonylamino-2-(3,5-dichloro-4-hydroxy-phenyl)-acetylamino]-methoxycarbonyl-methyl}-3-iodo-2-methoxy-phenyl)-1H-indol-3-yl]-propionic acid tert-butyl ester 
• 872876-83-0 (R,R)-(6'-iodo-N-carbobenzyloxytryptophyl)-3',5'-dichloro-4'-hydroxyphenylglycine tert-butyl ester 
• 872877-10-6 (R,R)-N-tert-butoxycarbonyl-3',5'-dichloro-4'-hydroxyphenylglycyl-4'-hydroxy-3',5'-diiodophenylglycine methyl ester 
• 872877-12-8 (R,R)-N-tert-butoxycarbonyl-3',5'-dichloro-4'-methoxyphenylglycyl-3',5'-diiodo-4'-methoxyphenylglycine methyl ester 
• 872876-81-8 (R)-3',5'-dichloro-4'-hydroxyphenylglycine tert-butyl ester 
• 26973-43-3 (R)-2-((tert-butoxycarbonyl)amino)-2-(3,5-dichloro-4-hydroxyphenyl)acetic acid 

Relevant articles and documents

STRUCTURE OF COMPLESTATIN, A VERY STRONG INHIBITOR OF PROTEASE ACTIVITY OF COMPLEMENT IN THE HUMAN COMPLEMENT SYSTEM

The structure of complestatin, which strongly inhibits the protease activity of complements in the human complement system, has been determined as shown in Fig.2 mainly based on HMBC.Its structure is closely related to glycopeptide antibiotics.

Next-Generation Total Synthesis of Vancomycin

A next-generation total synthesis of vancomycin aglycon is detailed that was achieved in 17 steps (longest linear sequence, LLS) from the constituent amino acid subunits with kinetically controlled diastereoselective introduction of all three elements of atropisomerism. In addition to new syntheses of three of the seven amino acid subunits, highlights of the approach include a ligand-controlled atroposelective one-pot Miyaura borylation-Suzuki coupling sequence for introduction of the AB biaryl axis of chirality (>20:1 dr), an essentially instantaneous and scalable macrolactamization of the AB ring system nearly free of competitive epimerization (>30:1 dr), and two room-temperature atroposelective intramolecular SNAr cyclizations for sequential CD (8:1 dr) and DE ring closures (14:1 dr) that benefit from both preorganization by the preformed AB ring system and subtle substituent effects. Combined with a protecting group free two-step enzymatic glycosylation of vancomycin aglycon, this provides a 19-step total synthesis of vancomycin. The approach paves the way for large-scale synthetic preparation of pocket-modified vancomycin analogues that directly address the underlying mechanism of resistance to vancomycin.

Synthesis of linear tripeptides for right-hand segments of complestatin

This paper concerns a synthetic study of the right-hand segment of complestatin, an inhibitor of gp120-CD4 receptor. The effective synthesis of four important precursors for the right-hand segment of complestatin is described. Two of them are the precurso